<DOC>
	<DOCNO>NCT01516840</DOCNO>
	<brief_summary>The objective study evaluate efficacy , safety , pharmacokinetics ( PK ) pharmacodynamics ( PD ) two different dosage rivaroxaban treatment deep vein thrombosis ( DVT ) prevention occurrence recurrence DVT pulmonary embolism ( PE ) Japanese patient acute symptomatic DVT without symptomatic PE .</brief_summary>
	<brief_title>Venous Thromboembolism ( VTE ) Treatment Study Japanese Deep Vein Thrombosis ( DVT ) Patients</brief_title>
	<detailed_description>The general design trial open label Rivaroxaban reference arm . However , two group Rivaroxaban arm initial 3 week . Between two group initial period , study blind .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Men woman &gt; /= 20 year age patient confirm acute symptomatic proximal deep vein thrombosis ( DVT ) without symptomatic pulmonary embolism ( PE ) Thrombectomy , insertion caval filter , use fibrinolytic agent treat current episode DVT More 48 hour prerandomization treatment therapeutic dosage anticoagulant treatment single dose warfarin onset current episode DVT randomization Calculated creatinine clearance ( CLCR ) &lt; 30 mL/min Subjects hepatic disease associate coagulopathy lead clinically relevant bleeding risk Active bleeding high risk bleed contraindicate treatment unfractioned Heparin ( UFH ) warfarin Systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>acute symptomatic deep vein thrombosis</keyword>
</DOC>